Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $5.6 million.

  • Voyager Therapeutics' Other Non-Current Assets rose 9533.75% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 9533.75%. This contributed to the annual value of $2.9 million for FY2024, which is 8041.43% up from last year.
  • Voyager Therapeutics' Other Non-Current Assets amounted to $5.6 million in Q3 2025, which was up 9533.75% from $2.9 million recorded in Q2 2025.
  • Voyager Therapeutics' 5-year Other Non-Current Assets high stood at $5.6 million for Q3 2025, and its period low was $1.5 million during Q2 2022.
  • Its 5-year average for Other Non-Current Assets is $2.3 million, with a median of $1.8 million in 2021.
  • As far as peak fluctuations go, Voyager Therapeutics' Other Non-Current Assets crashed by 3257.68% in 2022, and later skyrocketed by 9533.75% in 2025.
  • Over the past 5 years, Voyager Therapeutics' Other Non-Current Assets (Quarter) stood at $1.8 million in 2021, then dropped by 14.84% to $1.5 million in 2022, then rose by 5.15% to $1.6 million in 2023, then skyrocketed by 80.41% to $2.9 million in 2024, then surged by 95.34% to $5.6 million in 2025.
  • Its Other Non-Current Assets stands at $5.6 million for Q3 2025, versus $2.9 million for Q2 2025 and $2.9 million for Q1 2025.